<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054426</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-NHL-011</org_study_id>
    <nct_id>NCT05054426</nct_id>
  </id_info>
  <brief_title>Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL</brief_title>
  <acronym>NHL-011</acronym>
  <official_title>Intravenous Methotrexate 1g/m2 as Central Nervous System Prophylaxis for High Risk Diffuse Large B Cell Lymphoma: a Prospective, Phase III, Randomized, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Central nervous system (CNS) relapse is a devastating event of diffuse large B cell lymphoma&#xD;
      (DLBCL). It occurs in 4%-7% of DLBCL in general and the rate is considerably higher in&#xD;
      high-risk patients, resulting in a poor outcome.Effective methods of CNS prophylaxis have not&#xD;
      yet been developed. Evidence for intrathecal or intravenous MTX are both controversial. In&#xD;
      one previous study of PUMCH, IV MTX at a dose of 1g/m2 could significantly decrease the 2&#xD;
      year CNS relapse rate of high risk DLBCL(1.1% vs 12.1% for historic cohort, P=0.003). In&#xD;
      current study, the investigators are aiming to confirm its efficacy through phase III study&#xD;
      with intrathecal MTX as the controlled arm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective, phase III, multicenter, randomized, controlled study, the investigatirs&#xD;
      aim to compare the efficacy of intravenous MTX(IV arm) at a dose of 1g/m2 with intrathecal&#xD;
      MTX(IT arm) in terms of preventing CNS relapse. All the patients will recieve RCHOP regimen&#xD;
      as front-line treatment of DLBCL. Patients in IV arm will recieve 4 course of IV MTX, which&#xD;
      is incorporated into the RCHOP, naming R-MTX-CHOP regimen. Patients in IT arm will be given&#xD;
      intrathecal MTX for 4 courses (one time for each course). 2 year CNS relapse rate is the&#xD;
      primary endpoint while 2 year PFS, 2 year OS and safety are the secondary endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 8, 2021</start_date>
  <completion_date type="Anticipated">October 8, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 8, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 year CNS relapse rate</measure>
    <time_frame>2 year</time_frame>
    <description>CNS relapse was defined as positive CSF conventionalcytology, CSF flow cytometry, or biopsy. For those who had clinical symptoms indicating a CNS involvement and typical lesions on MRI, the investigators also considered a recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 year</time_frame>
    <description>from diagnosis to any event including progression, relapse and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 year</time_frame>
    <description>from diagnosis to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">488</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>intravenous MTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous methotrexate at a dose of 1g/m2 for 4 courses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intrathecal MTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intrathecal methotrexate 10mg at a time for 4 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>intravenous versus intrathecal methotrexate</description>
    <arm_group_label>intrathecal MTX</arm_group_label>
    <arm_group_label>intravenous MTX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age â‰¥ 18 years&#xD;
&#xD;
          -  with high CNS risk, which was defined as involvement of more than one extranodal site,&#xD;
             or involvement of particular extranodal sites such as bone marrow, breasts, testes,&#xD;
             paranasal sinuses, epidural space, adrenal glands, kidney and female genital system;&#xD;
&#xD;
          -  first-line treatment planned to be RCHOP&#xD;
&#xD;
          -  absence of CNS involvement at presentation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  primary CNS lymphoma&#xD;
&#xD;
          -  already have CNS involvement at diagnosis&#xD;
&#xD;
          -  primary mediastinal lymphoma, intravascular large B-cell lymphoma, DLBCL leg-type,&#xD;
             Burkitt lymphoma, high-grade lymphomas, double expressor lymphoma&#xD;
&#xD;
          -  with active infection or other malignancy&#xD;
&#xD;
          -  severe liver or kidney insufficiency&#xD;
&#xD;
          -  allergy to any medication we plan to use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daobin Zhou, MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Wang, MD.</last_name>
    <phone>8613810131294</phone>
    <email>wangweipumc@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daobin Zhou, MD.</last_name>
    <phone>8613901113623</phone>
    <email>zhoudb@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking union medical college hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daobin Zhou, MD.</last_name>
      <phone>8613901113623</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Wang W, Zhang Y, Zhang L, Yang C, Feng J, Cai H, Chen M, Cao X, Zhuang J, Zhu T, Duan M, Zhang W, Li J, Zhou D. Intravenous methotrexate at a dose of 1 g/m(2) incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: A prospective, historic controlled study. Am J Hematol. 2020 Apr;95(4):E80-E83. doi: 10.1002/ajh.25723. Epub 2020 Jan 22.</citation>
    <PMID>31925808</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>YanZhang</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>central nervous system prophylaxis</keyword>
  <keyword>methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

